Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Necuparanib + Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Cancer
NCT01621243Phase 2Terminated
- Sponsor
- Momenta Pharmaceuticals
- Start
- May 2012
- Primary completion
- Oct 2016
- Modality
- Polymer-based Nanoparticles, Bivalent/Multivalent Binders
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of necuparanib in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Momenta Pharmaceuticals. Primary endpoints: Safety and tolerability and Overall Survival. Started May 2012; status: terminated.
02
Drugs
necuparanib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01621243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01621243.